Cytokine Release Syndrome Stratification
Solutions Accelerated by IsoPlexis
- Cytokine Release Syndrome Prediction
Apply PSI to inflammation of CAR T-cell product correlates to Grade 3+ CRS, pre-infusion1
Uncover the polyfunctional immune cell subsets which correlate to IRAEs in immunotherapy and discover biomarker correlates to inflammation.
Preinfusion prediction of in vivo CRS in CAR-T patients, not possible with legacy technologies
IsoPlexis’ PSI is able to stratify severe CRS occurrence in CAR-T patients
PSI of the pre-infusion CAR-T product was found to associate with in vivo CRS
Higher CAR-T product PSI was found to statistically associate with grade 3+ CRS (p = 0.0174). PSI was measured across CD4+ and CD8+ samples from 20 patients.
In particular, there were large increases in the production of effector and stimulatory cytokines in the 3+ CRS cohort. These results suggest that the combination of frequency and cytokine production levels of polyfunctional T cells in the product associate with toxicity to treatment with CAR-T cells.1